Cargando…
Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
BACKGROUND: Childhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV). The effects of all-oral direct-acting antiviral therapy (DAA) on both the HCV infection as well as the state of cancer remission have not been well investigated in this population. AIM:...
Autores principales: | El-Shabrawi, Mortada HF, Sherief, Laila M, Yakoot, Mostafa, Kamal, Naglaa M, Almalky, Mohamed A, AbdElgawad, Manal M, Mahfouz, Aml A, Helmy, Sherine, Kamal, Enas M, Attia, Dina, El-Khayat, Hisham R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718790/ https://www.ncbi.nlm.nih.gov/pubmed/31531319 http://dx.doi.org/10.12998/wjcc.v7.i16.2247 |
Ejemplares similares
-
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017) -
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016) -
Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
por: Yakoot, Mostafa, et al.
Publicado: (2017) -
Congenital chloride losing diarrhea: A single center experience in a highly consanguineous population
por: Kamal, Naglaa M., et al.
Publicado: (2019) -
Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)